The natural progression of the neurofibromas to a stage of advanced immune evasion, evidenced by co-expression of IDO1 and PD-L1, indicates that porcine NF1 models may be an ideal platform for the study of the biology of neurofibroma advancement and the development of therapies that effectively combine checkpoint inhibitors. This evidence concerns the gene IDO1 and neurofibroma.